News|Articles|October 7, 2024
A Streamlined Platform Process to Accelerate Biotherapeutics from Gene to Clinic
Author(s)Catalent
Harmonizing technological innovation and a platform approach in biomanufacturing can reduce time and cost barriers to produce stable, high-expressing antibody-based therapeutics.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Why Biopharma Developers Should Care About FDA’s New Personalized Therapy Approval Process
2
Chiesi–Aliada Partnership Advances BBB-Crossing Technology for Lysosomal Storage Disorders
3
How Advanced PK/TK Protocols Strengthen Data Integrity
4
